Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer

January 31st 2025

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes

January 30th 2025

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

January 29th 2025

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

January 29th 2025

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

January 28th 2025

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

January 28th 2025

Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.

Clinical Perspectives: Use of CDK4/6i After CDK4/6i

January 28th 2025

Panelists discuss potential treatment options for patients following progression on CDK4/6 inhibitors (i) in HR+/HER2– metastatic breast cancer.

Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions

January 27th 2025

Panelists discuss how in-house testing significantly reduces turnaround times by eliminating send-out delays and courier dependencies. This enables immediate sample processing, allowing for faster results delivery and prompt clinical decision-making. Health care facilities can optimize workflows through automated systems, clear communication protocols, and standardized testing procedures, minimizing bottlenecks between departments and facilitating quicker diagnosis and treatment initiation.

Implementing In-House Biomarker Testing: Rationale and Key Considerations

January 27th 2025

Panelists discuss how implementing in-house biomarker testing can significantly enhance patient care through faster turnaround times and streamlined decision-making processes. This approach reduces dependence on external laboratories while enabling more immediate clinical interventions. Key implementation considerations include staff expertise, quality control protocols, equipment costs, regulatory compliance, and testing volume to ensure operational efficiency and return on investment

ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02

January 22nd 2025

Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21st 2025

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

January 21st 2025

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

January 21st 2025

Panelists discuss how first- and second-line treatment options for HR+ advanced/metastatic breast cancer, particularly the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy, are influenced by clinical factors such as bone metastasis, visceral crisis, and molecular phenotype, while also reviewing the latest clinical trial data, real-world outcomes, and comparative efficacy of ribociclib, abemaciclib, and palbociclib.

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

January 20th 2025

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges

January 20th 2025

Panelists discuss how in-house comprehensive genomic profiling (CGP) testing offers key benefits like reduced turnaround times, direct control over processes, and immediate access to testing resources. However, significant challenges include substantial initial capital investment, the need for specialized staff recruitment and retention, and ongoing equipment maintenance requirements. Health care facilities must carefully weigh these trade-offs, considering their patient volume, existing infrastructure, and financial capabilities before implementing in-house CGP services.

Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights

January 20th 2025

Panelists discuss how centralized biomarker testing outsources analysis to specialized laboratories while decentralized testing occurs in-house. In-house testing offers tighter workflow control and closer pathology collaboration but requires more resources, whereas send-out testing leverages external expertise.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

January 17th 2025

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

January 16th 2025

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.